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Somatic hypermutation of Ig genes enables B cells of the germinal center to generate high-
affi  nity immunoglobulin variants. Key intermediates in somatic hypermutation are deoxy-
uridine lesions, introduced by activation-induced cytidine deaminase. These lesions can be 
processed further to abasic sites by uracil DNA glycosylase. Mutagenic replication of de-
oxyuridine, or of its abasic derivative, by translesion synthesis polymerases is hypothesized 
to underlie somatic hypermutation.
Rev1 is a translesion synthesis polymerase that in vitro incorporates uniquely deoxycyti-
dine opposite deoxyuridine and abasic residues. To investigate a role of Rev1 in mammalian 
somatic hypermutation we have generated mice defi  cient for Rev1. Although Rev1−/− mice 
display transient growth retardation, proliferation of Rev1−/− LPS-stimulated B cells is 
indistinguishable from wild-type cells. In mutated Ig genes from Rev1−/− mice, C to G 
transversions were virtually absent in the nontranscribed (coding) strand and reduced in the 
transcribed strand. This defect is associated with an increase of A to T, C to A, and T to C 
substitutions. These results indicate that Rev1 incorporates deoxycytidine residues, most 
likely opposite abasic nucleotides, during somatic hypermutation. In addition, loss of Rev1 
causes compensatory increase in mutagenesis by other translesion synthesis polymerases.
DNA translesion synthesis (TLS) is a backup 
replication pathway that, in contrast to replica-
tive polymerases δ and ε, is capable of replica-
ting damaged nucleotides that confer helical 
distortion to the DNA template. Replication 
of the damaged nucleotide by TLS is believed 
to safeguard the perpetuation of replication in 
the presence of unrepaired DNA damage, al-
beit frequently at the expense of misincorpora-
tions. The Y family of DNA polymerases in 
mammals is a major class of TLS polymerases 
comprising the polymerases η, ι, κ, and Rev1 
(1). In vitro, the catalytic activity of mamma-
lian Rev1 is limited to the highly distributive 
incorporation of cytosine residues opposite de-
oxyuridine residues and abasic nucleotides (2, 
3). Analysis of TLS at site-specifi  cally damaged 
DNA templates in Saccharomyces cerevisiae sup-
ports an important role of Rev1 in the bypass 
of abasic sites in vivo (4). In addition, Rev1-
  defi  cient chicken DT40 cells and hypomorphic 
mouse Rev1 mutant cells display hypersensitiv-
ity to a variety of genotoxic agents (5, 6). The 
infrequent mutations to deoxycytidine induced 
by these agents in Rev1-profi  cient S. cerevisiae 
suggests a second (noncatalytic) role for Rev1, 
possibly by recruiting other TLS polymerases. 
In agreement, TLS polymerases η, ι, κ, as well 
as the Rev7 TLS-associated protein, interact 
with a COOH-terminal domain of Rev1 (ref-
erences 7–10; unpublished data).
Deoxyuridine and abasic sites are essential 
triggers for somatic hypermutation (SHM), a 
process of antibody diversifi  cation in which the 
variable regions of Ig heavy (IgH) and light 
(IgL) chain genes in proliferating B cells of the 
germinal center mutate at an extremely high 
rate (11). This is followed by clonal selection of 
the cells that express Ig with increased affi   nity 
toward the antigen (12). SHM is triggered by 
deamination to uracil of deoxycytidines within 
Ig genes by the activation-induced deoxycyti-
dine deaminase (AID) (11, 13). Subsequent 
processing by uracil DNA glycosylase (UNG) 
can generate abasic sites that may be bypassed 
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by one or more of the TLS polymerases (14). In a second 
phase of SHM, DNA mismatch repair may induce single-
stranded gaps at sites of mispaired deoxyuridine residues, fol-
lowed by fi  lling the gaps by mutagenic TLS (11, 15). To 
investigate involvement of the Rev1 TLS polymerase in 
SHM, we have generated and analyzed Rev1-defi  cient mice.
RESULTS AND DISCUSSION
Using conventional gene targeting we deleted exon 10 of 
Rev1 encoding the conserved S(C/I)DE amino acid sequence 
essential for the catalytic activity of Y family DNA polymer-
ases (Fig. 1, A and B). Rev1+/– chimeric mice were obtained 
through blastocyst injection of heterozygous embryonic stem 
cells and crossed to C57BL/6 and 129/OLA mice. Rev1−/− 
off  spring from interbreeding after F1 and F2 backcrosses to 
both strains was obtained at 63% of the expected Mendelian 
ratios. Strikingly, Rev1–/– mice were not obtained beyond the 
F2 backcross into C57BL/6 mice, in contrast to backcrosses 
to 129/OLA. A similar strain dependence of the phenotype 
was found for mice defi  cient for the Rev3 TLS polymerase 
(16). The milder phenotypes of the 129/OLA mice are not 
caused by the pol ι defect of 129/OLA mice (17) due to the 
fact that (pol ι-profi  cient) Rev1–/– F1 hybrid mice of C57BL/6 
and 129/OLA crossings are viable. Rev1−/− mice from all 
strains displayed a transiently reduced weight in the absence 
of gross abnormalities (Fig. 2, A and B). Together, these re-
sults are consistent with a partially strain-dependent role for 
Rev1 in TLS of endogenous DNA damage.
Western blot analysis of cell lysates from Rev1–/– mouse 
embryonic fi   broblasts (MEFs), using a COOH-terminal 
α-Rev1 antiserum, confi  rmed the absence of protein in Rev1–/– 
cells (Fig. 1 C). Analysis of Rev1 transcripts from mouse kid-
ney by RT-PCR demonstrated the presence of only shortened 
transcripts in Rev1–/– cells (Fig. 1 D). Downstream of the dele-
tion of exon 10 all transcripts contained translational frame-
shifts (unpublished data). Based on these results we conclude 
that both the catalytic domain and the domain that interacts 
with other TLS polymerases and the Rev7 protein (7–10; un-
published data) are absent from our Rev1 mutant. In agree-
ment with a generalized defect in TLS of exogenous DNA 
damage, Rev1–/– MEFs are sensitive to several genotoxic agents 
tested, including short-wave UV light (unpublished data).
To investigate lymphopoiesis of Rev1–/– mice, we ana-
lyzed the cellularity and the composition of B and T cell sub-
sets of primary and secondary lymphatic organs like thymus, 
spleen, lymph nodes, and bone marrow. Consistent with the 
moderately reduced size of 7-wk-old Rev1–/– mice (Fig. 2), 
a proportional reduction in the cellularity of lymphoid organs 
was observed (Fig. 3 A). The normal frequency of all tested 
lymphoid subsets suggests that qualitative aspects of lympho-
cyte development are not impaired by the absence of Rev1 
Figure 1.  Targeted disruption of Rev1. (A, top) the genomic region of 
Rev1 that encodes the catalytic domain of Rev1. Vertical bold sections 
denote exons. SCDE, exon 10 encoding the catalytic domain of Rev1. Hori-
zontal bold sections denote regions homologous to the targeting vector. 
(A, middle) Targeting vector pSCDE-hygro to delete exon 10. Hyg, pPGK-
hygromycine cassette; TK, pPGK-thymidine kinase cassette. Arrows indi-
cate direction of transcription. (A, bottom) Targeted Rev1 allele. Probes 
A and B, DNA fragments used to analyze gene-targeting events. Ba, BamHI; 
Bg, BglII; K, KpnI; N, NcoI. (B) Southern blot of genomic mouse DNA 
  digested with KpnI and hybridized with probe A. Fragment sizes indicate 
the following alleles: 22 kbp, wild type; 11 kbp, Rev1−/−. 1, Rev1+/+; 
2, Rev1+/−; 3, Rev1−/−. (C) Western blot of MEF lysates hybridized with an 
α-Rev1 antiserum. Arrow indicates position of Rev1. 1, Rev1+/+; 2, 
Rev1−/−. (D) PCR products of Rev1 cDNA amplifi  ed from Rev1−/− kidneys. 
PCR products of exons 10–15 (left) and exons 8–15 (right). 1, size marker; 
2, Rev1+/+; 3, Rev1−/−. In the left panel, in lane 3 no PCR product is 
  detected as a consequence of the deletion of exon 10 in the mutant.
Figure 2.  Retarded growth of Rev1−/− mice. (A) 3-wk-old wild-type 
(top) and Rev1−/− (bottom) littermates illustrating the reduced body size 
in young Rev1−/− mice. (B) Growth characteristics of Rev1−/− mice be-
tween 3 and 52 wk after birth, expressed as the percentage of weight of 
wild-type mice. Males (solid bars); females (hatched bars). Each data point 
represents the mean of 7–10 mice.JEM VOL. 203, February 20, 2006  321
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(Table S1, available at http://www.jem.org/cgi/content/full/
jem.20052227/DC1). To determine whether the lack of Rev1 
activity has any impact on the proliferative capacity of mature 
B cells we determined proliferation of Rev1−/− and wild-type B 
cells in vitro after polyclonal stimulation with LPS. Proliferation 
characteristics of Rev1–/– and wild-type B cells were superim-
posable (Fig. 3 B), demonstrating that Rev1 defi  ciency does not 
impair proliferation of B cells. Similarly, the frequency of live, 
apoptotic, and dead B cells was normal in the mutant (Fig. 3 C). 
These results contrast with a previous report (5) showing that 
Rev1 defi  ciency causes a slower expansion rate and increased 
spontaneous apoptosis in the chicken DT40 B cell line.
To address the role of Rev1 in mammalian SHM, single 
class-switched (IgM−IgD−) memory B cells expressing a Igλ1 
light chain were isolated from mice derived from intercrosses 
of F2 backcrosses to C57BL/6. PCR amplifi  cation and direct 
sequencing of the rearranged Vλ1 gene segment from single 
cells was performed to determine the distribution, frequency, 
and base exchange pattern of somatic mutations as well as 
the frequency of memory B cells carrying a mutated Vλ1 
gene (18). SHM, corrected for clonality of the mutations, 
occurs at a normal frequency in Rev1−/− B cells (Table I). 
Thus, regardless of the genotype, 40–41% of all analyzed 
class-switched B cells contained a mutated rearranged Vλ1 
gene segment. Taking only the mutated Vλ1 sequences into 
account, the mutation frequency is 1.1% for wild-type and 
1.3% for Rev1–/– B cells. Likewise the distribution of mu-
tations along the Vλ1 segments, with a concentration at 
mutation hot spots within the complementarity-determin-
ing regions (CDR 1, 2, and 3), is similar in wild-type and 
Rev1–/– B cells (Fig. 4 A). In contrast, highly signifi  cant 
diff  erences in mutation spectra are found (Fig. 4, B and C; 
Table S2, available at http://www.jem.org/cgi/content/full/
jem.20052227/DC1). In the coding (nontranscribed) strand 
we fi  nd an almost complete absence of C to G transversions 
as well as a moderate decrease in G to C transversions (Fig. 
4, B and C). These results indicate a catalytic role of Rev1 
in incorporating dCMP during SHM in mammals, in agree-
ment with recent data demonstrating a role of the Rev1 
catalytic domain in SHM in chicken DT40 cells (19). The 
strand-specifi  c mutational defect at GC basepairs mimics that 
of Ung−/− B cells in which AID-induced deoxyuridine resi-
dues cannot be converted into abasic sites (15, 20). This result 
suggests that abasic sites, generated by subsequent AID and 
UNG activities on deoxycytidine residues, are the substrates 
for Rev1 in vivo. Because mice doubly defi  cient for the mis-
match repair gene Msh2 and for Ung have lost all transversion 
mutations at GC basepairs during SHM (15), the residual G 
to C transversions in Rev1−/− B cells are likely induced dur-
ing the second, mismatch repair-dependent phase of SHM. 
Compensating the strand-specifi  c defect in transversions at 
GC basepairs, the frequencies of A to T and C to A transver-
sions, as well as T to C transitions, are increased signifi  cantly 
in mutated Vλ1 gene sequences in Rev1−/− B cells (Fig. 4, 
B and C). These mutations may be caused by compensatory 
activity of pol η (21, 22) and/or other TLS polymerases. This 
result indicates that the interaction between Rev1 and other 
Figure 3.  Cellularity, proliferation, and survival of Rev1−/− B cells. 
(A) Cellularity of primary and secondary lymphoid organs of wild-type 
and Rev1−/− mice. At the age of 7 wk, the cellularity of primary and sec-
ondary lymphoid organs of wild-type and Rev1−/− mice were determined. 
The moderate reduction in cellularity likely is related to the reduced size 
of Rev1−/− mice in comparison with wild-type mice, rather than to a 
proliferation defect. See Fig. 2 A and Fig. 4 A. (B) Proliferation of CFSE-
loaded B cells from wild-type (thin line) and Rev1 mutant mice (bold line). 
As analyzed by fl  ow cytometry, LPS blasts proliferate normally in the ab-
sence of Rev1. (C) Survival of LPS-activated B cells. Live, apoptotic, and 
dead cells were distinguished by annexinV and propidium iodine (PI) using 
fl  ow cytometry. Survival and cell death are not signifi  cantly infl  uenced by 
Rev1 under these conditions. Wild type (white bars); Rev1−/− (black bars).
Table I.  Mutation frequencies of hypermutated Vλ1 gene 
segments in Rev1−/− memory B cells
WT Rev1
Cells analyzed 368 372
Cells mutated 41% (150) 40% (148)
Number of mutations 508 587
Mutation frequency 0.46% 0.53%
Actual mutation frequencya 1.1% 1.3%
aOnly mutated Vλ1 sequences are taken into account.322  SOMATIC HYPERMUTATION IN REV1-DEFICIENT MICE | Jansen et al. 
TLS polymerases, including pol η, is dispensable for their 
activity in SHM. In addition, deletion of the BRCT domain 
of Rev1 that regulates TLS of short-wave UV light–induced 
photoproducts by other TLS polymerases, including pol η, 
does not aff  ect SHM (6). This further supports the specifi  c 
involvement of the catalytic activity of the Rev1 protein in 
transversion   mutagenesis at GC basepairs.
In conclusion, we have demonstrated an important role 
of mammalian Rev1 in determining the mutation spectrum 
of hypermutating Ig genes, in a strand-biased fashion. This 
likely is achieved by the direct incorporation of deoxycyti-
dine opposite abasic sites, generated at cytidines via AID-me-
diated deamination and UNG activity, respectively.
MATERIALS AND METHODS
Generation of Rev1-defi  cient mice. Replacement of exon 10 of Rev1 in 
the 129/OLA-derived embryonic stem cell line E14 with a pPGK-hygromy-
cine cassette (Fig. 1 A) was performed according to established procedures. 
Gene targeting was analyzed by Southern blotting of KpnI-digested DNA 
and hybridization with probes A (Fig. 1 B) and B. Rev1+/− cells were used to 
generate C57BL/6-129/OLA chimeric mice that were crossed to 129/OLA 
and C57BL/6 mice. Tail DNA of progeny was genotyped in a multiplex 
PCR reaction (35 cycles at 94°C for 60 s, 53°C for 60 s, and 72°C for 90 s), 
using primers SCDEKA1 (5′-A  T  T  G  T  G  A  G  T  C  T  C  T  A  G  C  G  T  T  T  G  -3′) and 
SCDEKA2 (5′-G  C  T  G  G  A  A  T  T  G  A  A  A  T  T  C  T  A  G  G  -3′) amplifying the wild-
type allele, and primers SCDEKA1 and PGKPR1 (5′-G  C  T  T  C  C  A  T  T  G  C  T-
C  A  G  C  G  G  T  G  -3′) amplifying the mutant allele. All required permits were 
obtained (government permit number VVM/BD 00.235 D06 for generating 
the transgenic animals and University Animal Ethical Committee permit 
numbers DEC 01058 and DEC 03139).
Characterization of Rev1 expression. Rev1 cDNA was generated from 
kidney-derived RNA as described (6). Primers p13 (5′-G  C  A  G  A  T  A  T  A  C  C  A-
G  A  T  T  C  -3′) and p14 (5′-G  A  G  C  T  G  A  T  G  G  A  C  G  A  C  T  T  -3′) amplify a PCR 
fragment containing exons 8–15. Primers pSCDE (5′-G  T  C  A  G  C  T  G  C  G  A  T-
G  A  A  G  C  A  C  T  G  -3′) and p14 amplify a product encompassing exons 10–15 
(Fig. 1 D). PCR products were cloned and sequenced. Rev1 protein in lysates 
from immortalized MEFs was analyzed by immunoblotting as described (6).
Figure 4.  Somatic hypermutation of hypermutated Vλ1 genes from 
memory B cells of wild-type and Rev1−/− mice. (A) Distribution of 
point mutations in Rev1-defi  cient B cells. No signifi  cant differences are 
found between both genotypes. Wild-type mice (white bars); Rev1−/− mice 
(black bars). Mutations concentrate in CDR 1, 2, and 3 (underlined). Num-
bering of the codons is according to Kabat and Wu (22). (B) Nucleotide 
substitution profi  le (normalized to wild-type controls) of the hypermutated 
Vλ1 segments of the Igλ1 gene derived from Rev1−/− memory B cells. 
Highly signifi  cant differences are found between both genotypes. Wild-
type mice (white bars); Rev1−/− mice (black bars). Although the frequency 
of C to G and, to a lesser extent, G to C transversions are decreased, A to T 
and C to A transversions as well as T to C transitions are increased. Signifi  -
cant changes (Chi square test) are marked by 1, 2, 3, 4, and 5. The p-values 
are 0.006, 2 × 10−5, 0.005, 0.02, and 0.03, respectively. (C) Nucleotide 
 substitution  profi  le in hypermutated Vλ1 sequences from Rev1-profi  cient 
and -defi  cient B cells. The relative contribution of substitutions at all four 
basepairs is unaltered indicating no overall defect in SHM. (Left) Wild type, 
n = 508 mutations. (Right) Rev1−/−, n = 587 mutations.JEM VOL. 203, February 20, 2006  323
BRIEF DEFINITIVE REPORT
Flow cytometry. Single-cell suspensions from thymus, spleen, lymph 
nodes, and bone marrow were stained with specifi  c antibodies conjugated to 
FITC, PE, or APC or biotin; biotinylated monoclonal antibodies were re-
vealed with Streptavidin-PerCP or Streptavidin-APC. Antibodies were pur-
chased from BD Biosciences unless mentioned otherwise: CD8b-FITC 
(53–5.8), CD19-FITC (1D3), IgD-FITC (11-26c.2a), IgM-Fluos (331.12, 
self conjugated), CD3-PE (17A2), CD8-PE (53–6.7), CD19-PE (1D3), Vλ-
PE (LS136, self conjugated), CD4-APC (RM4-5), CD19-APC (1D3), cKit-
APC (CD117, clone 2B8), Thy1-APC (CD90, clone 53–2.1), biotinylated 
TCRγδ (GL3), biotinylated IgM (II/41), and streptavidin-APC. Analysis 
was performed on a FACScalibur.
Proliferation of LPS-stimulated B cells. Isolated splenocytes were la-
beled in serum-free IMDM medium for 10 min at 37°C with 5 μM carboxy 
fl  uorescein diacetate succinimidyl ester (CFSE; Molecular Probes). Next, the 
cells were cultured for 3 d in the presence of 25 μg/ml LPS and 7 μg/ml 
dextran sulfate. LPS blasts were stained with a PE-conjugated anti-CD19, 
and subsequently with APC-conjugated annexin V and propidium iodine, 
and analyzed on a FACScalibur (Becton Dickinson).
Analysis of somatic hypermutation. Single live IgD− and IgM− (FITC−) 
and CD19+ (APC+) and Vλ1+ (PE+) B cells were isolated from spleens of 
3–5-mo-old mice. Analysis of SHM in the rearranged Vλ1 gene segment by 
single-cell PCR was performed as described (18).
Mutation analysis. Multiple, nonimmunized, wild-type (n = 7) and Rev1−/− 
(n = 5) mice were analyzed, minimizing the incidence of clonally related 
  sequences (Table S2). Data represent mutations between codons 13 and 97 
of Vλ1 (23) after exclusion of putatively clonally related mutants.
Online supplemental material. Table S1 is a composition of B and T cell 
subsets of primary and secondary lymphatic organs of wild-type and Rev1−/− 
mice. No qualitative diff  erences are found between the genotypes. Table S2 
shows a complete mutational spectrum at the Vλ1 gene segment of wild-
type and Rev1−/− mice. All mutated Rev1-defi  cient and profi  cient clones 
used for analysis are shown. Online supplemental material is available at 
http://www.jem.org/cgi/content/full/jem.20052227/DC1.
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